Bristol Myers Squibb Company $BMY Shares Sold by Stiles Financial Services Inc

Stiles Financial Services Inc trimmed its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 12.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,078 shares of the biopharmaceutical company’s stock after selling 2,527 shares during the quarter. Stiles Financial Services Inc’s holdings in Bristol Myers Squibb were worth $837,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. IFP Advisors Inc boosted its holdings in shares of Bristol Myers Squibb by 18.5% in the second quarter. IFP Advisors Inc now owns 31,394 shares of the biopharmaceutical company’s stock valued at $1,453,000 after acquiring an additional 4,894 shares during the period. Financial Security Advisor Inc. boosted its holdings in shares of Bristol Myers Squibb by 7.6% in the second quarter. Financial Security Advisor Inc. now owns 4,741 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 335 shares during the period. Callan Family Office LLC boosted its holdings in shares of Bristol Myers Squibb by 236.1% in the second quarter. Callan Family Office LLC now owns 27,337 shares of the biopharmaceutical company’s stock valued at $1,265,000 after acquiring an additional 19,203 shares during the period. TFR Capital LLC. acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $207,000. Finally, Leo Wealth LLC boosted its holdings in shares of Bristol Myers Squibb by 551.2% in the second quarter. Leo Wealth LLC now owns 45,232 shares of the biopharmaceutical company’s stock valued at $2,094,000 after acquiring an additional 38,286 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.09% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BMY shares. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Daiwa America cut Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Saturday, September 27th. Citigroup cut their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, August 1st. Finally, Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $57.14.

Bristol Myers Squibb Trading Up 0.2%

NYSE:BMY opened at $44.65 on Friday. The stock has a fifty day moving average price of $46.27 and a two-hundred day moving average price of $48.22. The stock has a market capitalization of $90.88 billion, a price-to-earnings ratio of 18.00, a PEG ratio of 2.28 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. The firm had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.Bristol Myers Squibb’s revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be given a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.6%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.